Medical Writing Medical Writing in Paediatrics ADHD: A true neurodevelopmental disorder?

Volume 21, Issue 2 - Medical Writing in Paediatrics

ADHD: A true neurodevelopmental disorder?


Attention-deficit/hyperactivity disorder (ADHD) is one of the most common childhood disorders. First described in 1798 by Alexander Crichton, ADHD became widely known outside the medical profession with the publication of the story of Fidgety Phil (‘Zappelphilipp’) in Heinrich Hoffman's book ‘Struwwelpeter’ in 1846. Since then, scientists and clinicians have been struggling to understand its causes. To date, there is neither a genetic test nor a brain scan to diagnose ADHD due to the fact that it is a heterogeneous collection of behaviours that appear to have different causes and symptoms. In view of the lack of an objective diagnostic method, the major difficulty that specialists face is to decide where to set the threshold between behaviours and states of mind that require medication or behavioural treatment and differences that can be left alone. The increased rate in diagnosis and stimulant use in ADHD recently raises several issues, notably, are we setting lower diagnostic thresholds because of societies’ intolerance of behaviours and impairments associated with ADHD? This article discusses some of the controversies in ADHD diagnosis and treatment, including many medical, social, and ethical aspects.

Download the full article


  1. Stergiakouli E, Thapar A. Fitting the pieces together: current research on the genetic basis of attention-deficit/hyperactivity disorder (ADHD). Neuropsychiatr Dis Treat 2010;6:551–60.
  2. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005;366:237–48.
  3. Wikipedia. Attention-deficit hyperactivity disorder controversies Available from:
  4. Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990;29:546–57.
  5. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder (ADHD): full guideline: Diagnosis and management of ADHD in children, young people and adults [National Clinical Practice Guideline Number 72]; 2008. Available from:
  6. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313–23.
  7. Thapar A, Cooper M, Jefferies R, et al. What causes attention deficit hyperactivity disorder? Arch Dis Child 2012;97:260–5.
  8. Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, et al. Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am J Hum Genet 2008;83:504–10.
  9. O'Donovan MC, Kirov G, Owen MJ. Phenotypic variations on the theme of CNVs. Nat Genet 2008;40:1392–3.
  10. Williams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010;376:1401–8.
  11. Williams NM, Franke B, Mick E, et al. Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. Am J Psychiatry 2012;169:195–204.
  12. Doyle AE, Faraone SV. Familial links between attention deficit hyperactivity disorder, conduct disorder, and bipolar disorder. Curr Psychiatry Rep 2002;4:146–52.
  13. Durston S. Imaging genetics in ADHD. Neuroimage 2010;53:832–8.
  14. Bédard AC, Schulz KP, Cook EH Jr, et al. Dopamine transporter gene variation modulates activation of striatum in youth with ADHD. Neuroimage 2010;53:935–42.
  15. Narr KL, Woods RP, Lin J, et al. Widespread cortical thinning is a robust anatomical marker for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2009;48:1014–22.
  16. Sagiv SK, Thurston SW, Bellinger DC, et al. Prenatal organochlorine exposure and behaviors associated with attention deficit hyperactivity disorder in school-aged children. Am J Epidemiol 2010;171:593–601.
  17. Ferguson CJ. The influence of television and video game use on attention and school problems: a multivariate analysis with other risk factors controlled. J Psychiatr Res 2011;45:808–13.
  18. Szasz TS. Pharmacracy: medicine and politics in America /// Pharmacracy: Medicine and politics in America. Westport, Connecticut: Praeger; 2001. p.212.
  19. Hartmann T, Ratey JJ. ADD success stories: a guide to fulfillment for families with attention deficit disorder: maps, guidebooks, and travelogues for hunters in this farmer's world. Grass Valley, California: Underwood Books; 1995.
  20. Jensen PS, Mrazek D, Knapp PK, et al. Evolution and revolution in child psychiatry: ADHD as a disorder of adaptation. J Am Acad Child Adolesc Psychiatry 1997;36:1672–9; discussion 1679–81.
  21. Born to Explore. Evolution, creativity and ADD: the other side of ADD/ADHD Available from:
  22. Eisenberg DT, Campbell B, Gray PB, et al. Dopamine receptor genetic polymorphisms and body composition in undernourished pastoralists: an exploration of nutrition indices among nomadic and recently settled Ariaal men of northern Kenya. BMC Evol Biol 2008;8:173–84.
  23. Williams J, Taylor E. The evolution of hyperactivity, impulsivity and cognitive diversity. J R Soc Interface 2006;3:399–413.
  24. Timimi S, Taylor E. ADHD is best understood as a cultural construct. Br J Psychiatry 2004;184:8–9.
  25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders text revision (DSM-IV-TR). 4th ed. Washington, DC, USA; 2000.
  26. Berger I. Diagnosis of attention deficit hyperactivity disorder: much ado about something. Isr Med Assoc J 2011;13:571–4.
  27. Miller DJ, Derefinko KJ, Lynam DR, et al. Impulsivity and attention deficit-hyperactivity disorder: subtype classification using the UPPS Impulsive Behavior Scale. J Psychopathol Behav Assess 2010;32:323–32.
  28. Diamond A. Attention-deficit disorder (attention-deficit/hyperactivity disorder without hyperactivity): a neurobiologically and behaviorally distinct disorder from attention deficit/hyperactivity (with hyperactivity). Dev Psychopathol 2005;17:807–25.
  29. Milich R, Balentine AC, Lynam DR. ADHD combined type and ADHD predominantly inattentive type are distinct and unrelated disorders. Clin Psych: Res Pract 2001;8:463–88.
  30. Park JH, Lee SI, Schachar RJ. Reliability and validity of the child and adolescent functioning impairment scale in children with attention-deficit/hyperactivity disorder. Psychiatry Invest 2011;8:113–22.
  31. Rousseau C, Measham T, Bathiche-Suidan M. DSM IV, culture and child psychiatry. J Can Acad Child Adolesc Psychiatry 2008;17:69–75.
  32. Singh I. Beyond polemics: science and ethics of ADHD. Nat Rev Neurosci 2008;9:957–64.
  33. American Academy of Pediatrics. Committee on quality improvement. Clinical practice guideline: diagnosis and evaluation of the child with ADHD. Pediatrics 2000;105:1158–70.
  34. Antshel KM, Hargrave TM, Simonescu M, et al. Advances in understanding and treating ADHD. BMC Med 2011;9:72–83.
  35. Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 2011;11:176–83.
  36. Faraone SV, Biederman J, Spencer TJ, et al. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 2006;8:4.
  37. Aagaard L, Hansen EH. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat 2011;7:729–44.
  38. Sonuga-Barke EJ, Coghill D, Wigal T, et al. Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control. J Child Adolesc Psychopharmacol 2009;19:683–90.
  39. Curatolo P, D'Agati E, Moavero R. The neurobiological basis of ADHD. Ital J Pediatr 2010;36:79–85.
  40. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009;11:203–26.
  41. Faraone SV, Glatt SJ. Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD. J Atten Disord 2010;13:532–8.
  42. Hammerness P, Wilens T, Mick E, et al. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 2009;155:84–9.
  43. Mahon AD, Stephens BR, Cole AS. Exercise responses in boys with attention deficit/hyperactivity disorder: effects of stimulant medication. J Atten Disord 2008;12:170–6.
  44. Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics 2009;124:e75–80.
  45. Yu ZJ, Parker-Kotler C, Tran K, et al. Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 2010;12:111–5.
  46. Ponsa I, Ramos-Quiroga JA, Ribasés M, et al. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate. Mutat Res 2009;666:44–9.
  47. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008;47:209–18.
  48. Meijer WM, Faber A, van den Ban E, et al. Current issues around the pharmacotherapy of ADHD in children and adults. Pharm World Sci 2009;31:509–16.
  49. Savill N, Bushe CJ. A systematic review of the safety information contained within the summaries of product characteristics of medications licensed in the United Kingdom for attention deficit hyperactivity disorder. How does the safety prescribing advice compare with national guidance? Child Adolesc Psychiatry Ment Health 2012;6:2. [Epub ahead of print]. PMID: 22234242.
  50. Pellow J, Solomon EM, Barnard CN. Complementary and alternative medical therapies for children with attention-deficit/hyperactivity disorder (ADHD). Altern Med Rev 2011;16:323–37.
  51. Lan Y, Zhang LL, Luo R. Attention deficit hyperactivity disorder in children: comparative efficacy of traditional Chinese medicine and methylphenidate. J Int Med Res 2009;37:939–48.
  52. Salehi B, Imani R, Mohammadi MR, et al. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:76–80.
  53. Raz R, Carasso RL, Yehuda S. The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 2009;19:167–77.
  54. Johnson M, Ostlund S, Fransson G, et al. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 2009;12:394–401.
  55. Arns M, de Ridder S, Strehl U, et al. Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis. Clin EEG Neurosci 2009;40:180–9.
  56. Brinkman WB, Epstein JN. Treatment planning for children with attention-deficit/hyperactivity disorder: treatment utilization and family preferences. Patient Prefer Adherence 2011;5:45–56.
  57. Furman LM. Attention-deficit hyperactivity disorder (ADHD): does new research support old concepts? J Child Neurol 2008;23:775–84.
  58. Lange KW, Reichl S, Lange KM, et al. The history of attention deficit hyperactivity disorder. Atten Defic Hyperact Disord 2010;2:241–55.
  59. Singh I. A disorder of anger and aggression: children's perspectives on attention deficit/hyperactivity disorder in the UK. Soc Sci Med 2011;73:889–96.
  60. Scheffler RM, Hinshaw SP, Modrek S, et al. The global market for ADHD medications. Health Aff (Millwood) 2007;26:450–7.
  61. Garfield CF, Dorsey ER, Zhu S, et al. Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000–2010. Acad Pediatr 2012; 12:110–6. PMID: 22326727.
  62. Sciutto MJ, Eisenberg M. Evaluating the evidence for and against the overdiagnosis of ADHD. J Atten Disord 2007;11:106–13.



Medical writing in paediatrics: Children and the future
Message from the President
Challenges of paediatric drug development and impact of paediatric legislation
Writing applications for Paediatric Investigation Plans and waivers
Preparing the Paediatric Investigation Plan application
ADHD: A true neurodevelopmental disorder?
Medicines information for patients: Insights into research and practice for medical writers
The MHRA perspective on the new pharmacovigilance legislation
Are stem cells the future of healthcare?
O, safety, quo vadis?
Crowdpower in the era of ‘health 2.0’
Networking effectively: Essential for being successful in business
The moving image and your business
Forgive me for repeating myself: Self-plagiarism in the medical literature
In the Bookstores
Journal Watch
The Webscout
Manuscript Writing
Regulatory Writing
English Grammar and Style
Out On Our Own

Member Login


The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board



Editorial Manager

  • Victoria White (Tampa, Florida, USA)
show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: